Wolfe Research Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN)

Research analysts at Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report issued to clients and investors on Friday, Marketbeat.com reports. The firm set an “outperform” rating and a $1,150.00 price target on the biopharmaceutical company’s stock. Wolfe Research’s target price suggests a potential upside of 51.95% from the company’s previous close.

A number of other research analysts also recently issued reports on REGN. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Evercore ISI dropped their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Citigroup began coverage on Regeneron Pharmaceuticals in a research report on Thursday. They issued a “neutral” rating and a $895.00 price objective for the company. Finally, BMO Capital Markets cut their target price on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,099.55.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $756.81 on Friday. The business has a 50-day moving average of $985.21 and a 200-day moving average of $1,033.97. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market capitalization of $83.17 billion, a price-to-earnings ratio of 18.73, a price-to-earnings-growth ratio of 2.86 and a beta of 0.15. Regeneron Pharmaceuticals has a 1 year low of $753.69 and a 1 year high of $1,211.20.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in REGN. Rakuten Securities Inc. boosted its position in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the period. Stephens Consulting LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $26,000. Sachetta LLC boosted its holdings in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the period. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $26,000. Finally, Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $28,000. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.